| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8738580 | International Journal of Antimicrobial Agents | 2018 | 17 Pages |
Abstract
Dalbavancin appears to be a viable candidate for treating BJI/osteomyelitis caused by Gram-positive cocci.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Michael A. Pfaller, Robert K. Flamm, Mariana Castanheira, Helio S. Sader, Rodrigo E. Mendes,